Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 5

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 5
---
 offering. The
placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The
placement agent is not purchasing or selling any of the securities we are offering and the placement agent is not required to arrange
the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay to the placement agent the placement
agent fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. There is no minimum
number of securities or amount of proceeds required as a condition to closing in this offering. Because there is no minimum offering amount
required as a condition to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly
reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell
an amount of securities sufficient to pursue our business goals described in this prospectus. In addition, because there is no escrow
trust or similar arrangement and no minimum offering amount, investors could be in a position where they have invested in our company,
but we are unable to fulfill all of our contemplated objectives due to a lack of interest in this offering. Further, any proceeds from
the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use
such funds to effectively implement our business plan. We will bear all costs associated with the offering. See “Plan of Distribution”
on page 35 of this prospectus for more information regarding these arrangements

We intend to use the proceeds from this offering
for general corporate purposes, including working capital. See “Use of Proceeds.”

On February 24, 2025,
we effected a reverse stock split of our common stock at a ratio of 1-for-5. Unless otherwise indicated, all financial information,
share numbers, option numbers, warrant numbers, other derivative security numbers and exercise prices appearing in this registration statement
have been adjusted to give effect to the reverse stock split.

Investing in our securities involves a high degree of risk. See “ Risk Factors” beginning on page 19 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is